PL EN
 
5-6/2010 vol. 64
Get citation
Evaluation of platelet functions in patients taking acetylsalicylic acid as a secondary stroke prevention
Beata Łabuz-Roszak 1
,
 
Krystyna Pierzchała 1
,
 
Agnieszka Machowska-Majchrzak 1
,
 
Aleksandra Porosińska 1
,
 
Maciej Wawrzyńczyk 1
 
 
 
More details
Hide details
1
Katedra i Klinika Neurologii SUM w Zabrzu Kierownik Kliniki: Prof. dr hab. n. med. Krystyna Pierzchała
 
 
Corresponding author
Beata Łabuz-Roszak   

Klinika Neurologii Śląski Uniwersytet Medyczny, ul. 3 Maja 13/15, 41-800 Zabrze, tel. +48 32 370 45 84
 
 
Ann. Acad. Med. Siles. 2010;64:54-63
 
Article (PDF)
References (46)
 
KEYWORDS
resistance to aspirin
stroke
transient ischemic attack
impedance aggregometry
multiple platelet function analyzer
 
ABSTRACT
Background:
In some patients taking acetylsalicylic acid (ASA) regularly no anti-aggregative eff ect is achieved. This phenomenon is called “aspirin resistance”. Until now, there are no unequivocal data concerning frequency and causes of aspirin resistance in patients taking ASA as secondary stroke prevention. The purpose of the study was to examine platelet functions in patients with diagnosed transient ischemic attack (TIA) or ischemic stroke in the acute phase whom ASA was applied.

Material and Methods:
We examined 70 patients with TIA or stroke treated in the Department of Neurology in Zabrze taking 75–150 mg ASA daily (mean age 68.7±11 years). The assessment of platelet function was performed by multiple platelet function analyzer using the method of impedance aggregometry in the whole blood.

Results:
Aspirin resistance was observed in 6 patients (8.6%). We found no correlation between platelet aggregation and dose, age, sex, time of examination, degree of motor incapability, hypertension, coronary disease, atrial fi brillation, old myocardial infarction. However, we observed correlation between presence of aspirin resistance and high LDL-cholesterol, high BMI and statin intake. No correlation was noted with other biochemical parameters and other drugs.

Conclusions:
The applied method allowed to detect phenomenon of aspirin resistance in some patients with stroke, who were taking ASA in the acute phase. The correlation between antiplatelet eff ect of ASA and either some stroke risk factors (high LDL-level and high BMI) or statin therapy was observed. The usage of multiple platelet function analyzer to monitor antiplatelet eff ect of ASA should be further examined.

 
REFERENCES (46)
1.
Jack D.B. One hundret years of aspirin. Lancet 1997; 350: 437-439.
Google Scholar
 
 
2.
Antiplatelet Trialist` Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
Google Scholar
 
 
3.
Postuła M., Kapłon A. Oporność na kwas acetylosalicylowy i jego kliniczne znaczenie. Kardiologia w praktyce. 2007; 3(3): 144–152.
Google Scholar
 
 
4.
Antithrombotic Trialist` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
Google Scholar
 
 
5.
Kamińska M., Musiał W.J., Osada J., Dąbrowska M. Problem „oporności” na leki przeciwpłytkowe. Terapia Kardiodiabetologia 2009; 4: 28–33.
Google Scholar
 
 
6.
Cabe D.J.H., Harrison P., Mackie I.J. i wsp. Assessment of the antiplatelet eff ects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005; 16(5): 269–280.
Google Scholar
 
 
7.
Toth O., Calatzis A., Penz S. i wsp. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb. Haemost. 2006; 96: 781– 788.
Google Scholar
 
 
8.
Sibbing D., Braun S., Jawansky S. i wsp. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiplate electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost. 2008; 99: 121–126.
Google Scholar
 
 
9.
Paniccia R., Antonucci E., Maggini N. i wsp. Assessment of platelet function on whole blood by multiplate electrode platelet aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am. J. Clin. Pathol. 2009; 131: 834–842.
Google Scholar
 
 
10.
Calatzis A., Spannagl M., Loreth R. Multiplate platelet function analysis – application and interpretation. V2.0/07.2007. Dynabyte medical, Monachium 2007.
Google Scholar
 
 
11.
Instrukcja obsługi Multiplate. V.060 403PL. Dynabyte medical, Monachium 2007.
Google Scholar
 
 
12.
Bernstein P.L., Jacobson B.F., Connor M.D., Becker P.J. Aspirin resistance in south African Caucasian patients with thrombotic cerebrovascular events. J. Neurol. Sci. 2009; 277(1-2): 80–82.
Google Scholar
 
 
13.
Bennet D., Yan B., Macgregor L. i wsp. A pilot study of resistance to aspirin in stroke patients. J. Clin. Neurosci. 2008; 15(11): 1204–1209.
Google Scholar
 
 
14.
Zimmermann N., Hohlfeld T. Clinical implications of aspirin resistance. Thromb. Haemost. 2008; 100(3): 379–390.
Google Scholar
 
 
15.
Dharmasaroja P. Aspirin non-responders in Thai ischaemic stroke/TIA patients. J. Med. Assoc. Thai. 2008; 91(6): 818–821.
Google Scholar
 
 
16.
Berrouschot J., Schwetlick B., von Twickel G. i wsp. Aspirin resistance in secondary stroke prevention. Acta Neurol. Scand. 2006; 113: 31–35.
Google Scholar
 
 
17.
Seok J.I., Joo I.S., Yoon J.H. i wsp. Can aspirin resistance be clinically predicted in stroke patients? Clin. Neurol. Neurosurg. 2008; 110(2): 110–116.
Google Scholar
 
 
18.
Żytkiewicz M., Giełwanowska L., Wojtasińska E. i wsp. Resistance to acetylsalicylic acid in patients after ischaemic stroke. Pol. Arch. Med. Wewn. 2008; 118(12): 727–732.
Google Scholar
 
 
19.
Postuła M., Tarchalska-Kryńska B., Filipiak K.J. i wsp. Factors responsible for aspirin resistance – can we identify them? Kardiol. Pol. 2010; 68(4): 412–413.
Google Scholar
 
 
20.
Karepov V., Tolpina G., Kuliczkowski W., Serebruany V. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after fi rst ischaemic stroke. Cerebrovasc. Dis. 2008; 26(3): 272–276.
Google Scholar
 
 
21.
Velik-Salchner C., Maier S., Innerhofer P. i wsp. Poin-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth. Analg. 2008; 107(6): 1798–1806.
Google Scholar
 
 
22.
Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack of minor ischemic stroke. N. Engl. J. Med. 1991; 325: 1261-1266.
Google Scholar
 
 
23.
Awtry E.H., Loscalza J. Aspirin. Circulation 2000; 101; 1026–1218.
Google Scholar
 
 
24.
Schror K. Aspirin and Platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 1997; 23: 349– 356.
Google Scholar
 
 
25.
Łabuz-Roszak B., Pierzchała K., Porosińska A. i wsp. Oporność na kwas acetylosalicylowy stosowany w prewencji wtórnej udaru mózgu. Badanie pilotażowe. Wiad. Lek. 2010; 3: 171–179.
Google Scholar
 
 
26.
Macchi L., Christaens L., Brizard A. i wsp. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 2002; 107: 5–49.
Google Scholar
 
 
27.
Alberts M.J., Bergman D.L., Molner E. i wsp. Antiplatelet eff ect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–178.
Google Scholar
 
 
28.
Gum P.A., Kottke-Marchand K., Poggio E.D. i wsp. Profi le and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001; 88: 230-235.
Google Scholar
 
 
29.
Hung J., Lam J.Y.T., Lacoste L. i wsp. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432–2436.
Google Scholar
 
 
30.
Davis J.W., Hartman C.R., Lewis H.D. i wsp. Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J. Lab. Clin. Med. 1985; 105: 479–483.
Google Scholar
 
 
31.
Cipollone F., Ciabattoni G., Patrono C. i wsp. Oxidant stress and aspirin-insensitive tromboxane synthesis in severe unstable angina. Circulation 2000; 102: 1007-1013.
Google Scholar
 
 
32.
Porosińska A., Pierzchała K. Koncepcje oporności na aspirynę. Neurol. Neurochirur. Pol. 2006: 40 (4): 313–319.
Google Scholar
 
 
33.
Friend M., Vucenik I., Miller M. Platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ 2003; 326: 82–83.
Google Scholar
 
 
34.
Jastrzębska M., Torbus-Lisiecka B., Pieczul- Mróz J. i wsp. Ocena funkcji płytek krwi i aktywności inhibitora aktywatora plazminogenu w chorobie niedokrwiennej serca w zależności od współistniejącej hiperlipoproteinemii i leczenia aspiryną. Pol. Arch. Med. Wewn. 1997; 98: 510–519.
Google Scholar
 
 
35.
O`Donnell C.J., Larson M.G., Tofl er G.H. i wsp. Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 2001; 103: 3051–3056.
Google Scholar
 
 
36.
Opper C., Clement C., Wesemann W. i wsp. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995; 113(2): 211–217.
Google Scholar
 
 
37.
Karam J.H., Grodsky G.M., Forsham P.H. Excessive insulin response to glucose in obese subjects as measured by immunochemical assays. Diabetes 1963;12:197– 204.
Google Scholar
 
 
38.
Trovati M., Anfossi G.: Infl uence of insulin and of insulin resistance on platelet and and vascular smooth muscle cell function. J. Diabetes Complications 2002; 16: 35–40.
Google Scholar
 
 
39.
Kamińska M., Osada J., Dąbrowska M. i wsp. Ocena przeciwpłytkowego działania aspiryny wśród pacjentów po zawale serca leczonych PCI w obserwacji półrocznej – wyniki wstępne. Pol. Przeg. Kardiol. 2007; 5: 335–341.
Google Scholar
 
 
40.
Catella-Lawson F., Reilly M.P., Kapoor S.C. i wsp. Cyclooksygenase inhibitors and the antiplatelet eff ects of aspirin. N. Engl. J. Med. 2001; 345: 1809–1817.
Google Scholar
 
 
41.
Kurth T., Glynn R.J., Walker A.M. i wsp. Inhibition of clinical benefi ts of aspirin on fi rst myocardial infarction by nonsteroidal anti-infl amatory drugs. Circulation 2003; 108: 1191–1195.
Google Scholar
 
 
42.
Sibbing D., Morath T., Stegherr J. i wsp. Impact of proton pump inhibitors on the antiplatelet eff ects of clopidogrel. Thromb. Haemost. 2009; 101(4): 714–719.
Google Scholar
 
 
43.
Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Eff ects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157(1): 148–153.
Google Scholar
 
 
44.
Siller-Matula J.M., Lang I.M., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet eff ect of clopidogrel. J. Am. Coll. Cardiol. 2008; 52(19): 1557–1563.
Google Scholar
 
 
45.
Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195–198.
Google Scholar
 
 
46.
Buchanan M., Verma S. Biological basis and clinical implications of acetylsalicylic acid resistance. Can. J. Cardiol. 2006; 22(2): 149–151.
Google Scholar
 
 
Share
Send by email
RELATED ARTICLE
The applications of posturography in selected neurological disorders
Patient with CADASIL – a diagnostic challenge
An unusual manifestation of clear cell carcinoma – case report
The impact of anemia on neurological and functional state in patients in acute stroke – preliminary report
Diagnostic and therapeutic difficulties in 32-year-old woman with stroke, patent foramen ovale and hereditary thrombophilia – case report
Indexes
 
Keywords index
Topics index
Authors index
eISSN:1734-025X
Journals System - logo


© 2006-2024 Journal hosting platform by Bentus
Scroll to top